Who Are We
Who Are We
The Subcutaneous Drug Development & Delivery Consortium was established in 2018 to fundamentally improve subcutaneous drug development and delivery. Motivated by this shared goal, members have come together to address key issues in the subcutaneous industry and expand subcutaneous technology use to improve patient outcomes.
To realize this purpose, the Subcutaneous Drug Development & Delivery Consortium focuses on bringing together a diverse group of key members of the subcutaneous community (i.e., industry, academia, regulatory, payers, etc.) in a precompetitive manner to collaboratively share their respective expertise and experiences.
While the Subcutaneous Drug Development & Delivery Consortium has accomplished much since its inauguration in 2018, members are eager to capitalize on recent successes by establishing a comprehensive strategic plan to guide targeted activities and efforts into the future that will ensure members’ ultimate vision and mission will be realized.
Consortium members are:
- A diverse group of key stakeholders in the SC community, including industry, academia, regulatory, and payers
- Collaborating to advance the most pressing issues and opportunities in subcutaneous dosage and delivery in a precompetitive manner
- Key decision makers within their organizations
All members have experience in at least one of the following areas:
- Pharmaceutical drug delivery
- Device development
- Commercialization
Overview of the Subcutaneous Drug Development & Delivery Consortium
The Subcutaneous Drug Development & Delivery Consortium is established as a 501 C 6 nonprofit, with a Governing Board composed of 1 primary and 1 backup member from each represented industry organization (~17 companies total) to oversee the Subcutaneous Drug Development & Delivery Consortium’s strategy, direction, and governance of 6 sub-teams
English